Background: Residual psoriasis has been typically observed in difficult-to-treat body sites despite long-term use of efficacious systemic therapies. Objectives: To localize the body sites of residual psoriasis resistent to long-term therapy with biologics or oral small molecules in a real-world clinical setting, and to further study the correlation between lesional localization and patients' quality of life.
Background: Residual psoriasis has been typically observed in difficult-to-treat body sites despite long-term use of efficacious systemic therapies. Objectives: To localize the body sites of residual psoriasis resistent to long-term therapy with biologics or oral small molecules in a real-world clinical setting, and to further study the correlation between lesional localization and patients' quality of life.
PSORIATIC PATIENTS UNDERGOING LONG-TERM THERAPY WITH BIOLOGICS AND ORAL SMALL MOLECULES: LOCALIZATION OF RESIDUAL PSORIASIS AND THE IMPACT ON QUALITY OF LIFE IN A REAL-WORLD CLINICAL SETTING
MUSLIMANI, MUHAMMAD ALI
2019/2020
Abstract
Background: Residual psoriasis has been typically observed in difficult-to-treat body sites despite long-term use of efficacious systemic therapies. Objectives: To localize the body sites of residual psoriasis resistent to long-term therapy with biologics or oral small molecules in a real-world clinical setting, and to further study the correlation between lesional localization and patients' quality of life.È consentito all'utente scaricare e condividere i documenti disponibili a testo pieno in UNITESI UNIPV nel rispetto della licenza Creative Commons del tipo CC BY NC ND.
Per maggiori informazioni e per verifiche sull'eventuale disponibilità del file scrivere a: unitesi@unipv.it.
https://hdl.handle.net/20.500.14239/25736